Takada eyeing potential Shire asset sales to pay down debt
Takeda Pharmaceutical may try and sell Shire's dry-eye drug once it completes the $62bn takeover purchase of the UK-listed biotech, according to a report on Thursday.
FTSE 100
8,078.86
17:14 25/04/24
n/a
n/a
FTSE 350
4,434.34
17:09 25/04/24
n/a
n/a
FTSE All-Share
4,387.94
16:49 25/04/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,750.48
17:09 25/04/24
3.90%
852.98
Shire Plc
4,690.00p
16:39 08/01/19
0.00%
0.00p
Shire's Xiidra drug is among various potential divestments being mulled by Takeda, according to a report from Bloomberg, with Takeda also looking at selling the Dublin-headquartered group's Natpara treatment for low blood calcium.
Takeda wants to raise cash so it can trim the huge levels of debt it is raising to fund the deal.